TRIO PHARMACEUTICALS INC.
Dual targeting antibody drugs for cancer treatment
- Sector
- Biotech
- Headquarters
- SAN DIEGO, CA
- Founded
- 2018
- Latest Form D
- $1.5M, Nov 2022
- Total capital
- $2.3M
- Federal grants
- $798K
- 2 awards · 2022–2024
- Rank in peer group#66 of 502
- Private capital raised
- $1.5M
- 1 Form D · last Nov 2022
- 48 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 6 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · A novel targeted antibody therapeutic to treat ovarian cancer$399K
- Private capital raisedForm D · SEC · 1st filing$1.5M
- Federal grantHealth and Human S · Phase I · A Dual Action Antibody Drug Conjugate to Treat Triple Negative Breast Cancer by Enhancing Tumor Immunity$399K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
3months
from TRIO PHARMACEUTICALS INC.’s first federal award to its first private round.
- First federal award · Aug 2022
- Health and Human S · $399K
- First Form D · Nov 2022
- $1.5M · 1st Form D
- Awards before first raise
- 1 award
An association in public records, not a cause or a prediction.
Standing among 502 peers
Line = medianBiotech · Molecule
- Federal grants#66 · top 13%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Reiner LausResearcherExecutive Officer, DirectorLinked by $399K in grants as PI
- Shivarupam BhowmikResearcherExecutive Officer, DirectorLinked by $399K in grants as PI
- Jeffrey FriedmanDirectorNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 6- PendingMulti-specific Protein Molecules And Uses ThereofUSPTOApplication 17420000
- PendingTargeted Activation Of Endogenous Cell DeathUSPTOApplication PCTUS2024048185
- PendingMulti-specific Protein Molecules And Uses ThereofUSPTOApplication 63540237
Show all 6 patent records
- Multi-specific Protein Molecules And Uses ThereofMar 24, 2022 · Application 17420000Pending
- Targeted Activation Of Endogenous Cell DeathApplication PCTUS2024048185Pending
- Multi-specific Protein Molecules And Uses ThereofApplication 63540237Pending
- Multi-specific Protein Molecules And Uses ThereofApplication PCTUS2020012139Pending
- Multi-specific Protein Molecules And Uses ThereofApplication 62788495Pending
- Targeted Activation Of Endogenous Cell DeathApplication 19522238Pending
Related companies, and why
- Peloton Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- OWIC TECHNOLOGIES, INC.Similar federal contract value in Biotech · null in contracts
- Beech Tree Labs, Inc.Similar federal contract value in Biotech · null in contracts
- Asha Therapeutics, LLCSimilar federal contract value in Biotech · null in contracts
- BIOCOLLECTIVE, LLCSimilar federal contract value in Biotech · null in contracts
- Flavocure Biotech, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .